Biohaven Pharmaceutical Holding Company Ltd. wants to be a player in neurological and neuropsychiatric diseases, but the company has yet to report a clinical trial success outside of its CGRP inhibitor platform for the treatment of migraine. The most recent setback, disclosed on 27 September, is the failure of the myeloperoxidase (MPO) enzyme inhibitor verdiperstat in multiple system atrophy (MSA) to differentiate from placebo on the primary and secondary endpoints in a Phase III trial.
Analysts consistently viewed the setback as a minor event for Biohaven since the company’s valuation is largely based on the continued commercial success of its sole product – Nurtec ODT (rimegepant) for acute treatment and prevention of migraine – and follow-on CGRP inhibitor zavegepant for migraine